Dashboard
Manage Tickers

GLUEMonte Rosa Therapeutics, Inc.

Nasdaq monterosatx.com


$ 5.86 $ 1.00 (20.66 %)    

Tuesday, 20-Aug-2024 15:59:39 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 5.84
$ 4.92
$ 5.84 x 100
-- x --
$ 4.87 - $ 5.89
$ 2.44 - $ 8.84
292,992
na
416.01M
$ 2.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-16-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-29-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

monte-rosa-therapeutics-has-dosed-the-first-participants-in-a-phase-1-single-ascending-dosemultiple-ascending-dose-healthy-volunteer-study-of-mrt-6160-a-vav1-directed-mgd-being-developed-for-systemic-and-neurological-autoimmune-diseases-initial-data-expected-in-q1-2025
Monte Rosa Therapeutics Has Dosed The Firs...
08/19/2024 11:11:06

wells-fargo-maintains-overweight-on-monte-rosa-therapeutics-lowers-price-target-to-17
Wells Fargo Maintains Overweight on Monte ...
08/12/2024 17:40:16

Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price tar...

monte-rosa-therapeutics-q2-2024-gaap-eps-043-beats-055-estimate-sales-4695m-beat-1349m-estimate-cash-position-of-2671m-is-expected-to-fund-operations-into-h1-2027
Monte Rosa Therapeutics Q2 2024 GAAP EPS $...
08/08/2024 12:12:09

Core News & Articles
Watching Monte Rosa Therapeutics, Zura Bio...
07/01/2024 15:29:49

https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-jump-at-least-300-says-piper-sandler/

piper-sandler-reiterates-overweight-on-monte-rosa-therapeutics-maintains-16-price-target
Piper Sandler Reiterates Overweight on Mon...
06/28/2024 17:37:00

Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and maintains $16 p...

monte-rosa-therapeutics-announced-progress-updates-for-its-two-lead-programs-mrt-2359-an-mgd-being-developed-for-myc-driven-solid-tumors-and-mrt-6160-a-vav1-directed-mgd-in-development-for-systemic-and-neurological-autoimmune-diseases
Monte Rosa Therapeutics Announced Progress...
06/27/2024 11:13:06

Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dos...

monte-rosa-therapeutics-presents-preclinical-data-at-eular-2024-regarding-mrt-6160-for-treatment-of-rheumatoid-arthritis
Monte Rosa Therapeutics Presents Preclinic...
06/14/2024 12:46:08

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantib...

wedbush-reiterates-outperform-on-monte-rosa-therapeutics-maintains-11-price-target
Wedbush Reiterates Outperform on Monte Ros...
05/22/2024 14:54:30

Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $11 price t...

monte-rosa-therapeutics-will-present-preclinical-data-at-digestive-disease-week-2024-data-showed-that-mrt-6160-mediated-degradation-of-vav1-inhibited-disease-progression-in-a-t-cell-transfer-murine-model-of-colitis
Monte Rosa Therapeutics Will Present Precl...
05/21/2024 11:08:58

VAV1 is a key signaling protein downstream of both the T-and B-cell receptors and its degradation has potential to treat multip...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
05/16/2024 12:06:53

monte-rosa-therapeutics-shares-are-trading-lower-after-the-company-announced-the-pricing-of-a-100-million-public-offering
Monte Rosa Therapeutics shares are trading...
05/16/2024 12:04:18

monte-rosa-therapeutics-reports-pricing-of-100m-public-offering
Monte Rosa Therapeutics Reports Pricing Of...
05/16/2024 11:16:41

The company announced the pricing of an underwritten public offering of 10.638 million shares of its common stock at a public o...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
05/15/2024 20:32:03

monte-rosa-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-no-size-or-amount-disclosed
Monte Rosa Therapeutics Announces Proposed...
05/15/2024 20:13:32

Monte Rosa Therapeutics, Inc. ("Monte Rosa") (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel mol...

monte-rosa-therapeutics-expects-its-cash-and-cash-equivalents-of-1978m-to-be-sufficient-to-fund-planned-operations-and-capital-expenditures-into-the-first-half-of-2026
Monte Rosa Therapeutics Expects Its Cash A...
05/09/2024 11:54:26

monte-rosa-therapeutics-q1-2024-gaap-eps-053-beats-059-estimate
Monte Rosa Therapeutics Q1 2024 GAAP EPS $...
05/09/2024 11:53:28

why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Westport Fuel Systems Shares Are Tradi...
03/26/2024 17:45:27

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
03/26/2024 17:31:10

monte-rosa-therapeutics-q4-earnings-insights
Monte Rosa Therapeutics: Q4 Earnings Insights
03/14/2024 13:05:05

monte-rosa-therapeutics-q4-eps-058-misses-033-estimate-cash-balance-of-237m-is-expected-to-provide-cash-runway-into-first-half-of-2026
Monte Rosa Therapeutics Q4 EPS $(0.58) Mis...
03/14/2024 11:12:53

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimat...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION